Enlivex Therapeutics (NASDAQ:ENLV) Hits New 1-Year Low - Should You Sell?

Key Points

• Enlivex Therapeutics hit a new 52-week low during Thursday trading, with shares falling to as low as $0.4277 before last trading at $6.9210.
• Analyst opinions are mixed, with ratings ranging from buy to sell; the current consensus from MarketBeat is Hold with a price target of $247.50.
• The company is a clinical-stage biopharmaceutical firm focused on immunotherapies, and its lead candidate is Allocetra, a cell therapy designed to recalibrate the innate immune system.

Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Get Free Report) hit a new 52-week low during trading on Thursday . The company traded as low as $0.4277 and last traded at $6.9210, with a volume of 816906 shares changing hands. The stock had previously closed at $7.2075.

Analyst Upgrades and Downgrades

A number of research firms have commented on ENLV. Wall Street Zen upgraded shares of Enlivex Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, April 25th. HC Wainwright upped their price target on Enlivex Therapeutics from $195.00 to $300.00 and gave the company a "buy" rating in a research report on Tuesday, April 7th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Enlivex Therapeutics in a research report on Friday, June 26th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $247.50.

Enlivex Therapeutics Stock Down 2.9%

The stock has a 50-day simple moving average of $0.69 and a 200 day simple moving average of $0.88. The company has a market cap of $1.66 billion, a PE ratio of -12.85 and a beta of 1.52.

Institutional Trading of Enlivex Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in Enlivex Therapeutics in the fourth quarter valued at approximately $33,000. Invesco Ltd. acquired a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at $43,000. XTX Topco Ltd raised its holdings in shares of Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company's stock valued at $43,000 after buying an additional 19,132 shares during the period. Jane Street Group LLC raised its holdings in shares of Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company's stock valued at $52,000 after buying an additional 52,553 shares during the period. Finally, Susquehanna International Group LLP acquired a new position in Enlivex Therapeutics during the 3rd quarter worth about $57,000. Institutional investors and hedge funds own 1.02% of the company's stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company's lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.